Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

Shigeaki Suzuki, Nobuhisa Ishikawa, Fumie Konoeda et al. · Neurology · 2017 · 391 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar et al. · Muscle & Nerve · 2019 · 247 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses

James F. Howard, Chafic Karam, Marcus Yountz et al. · Annals of Clinical and Translational Neurology · 2021 · 62 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17

SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)

Margarita Majem, E. García-Martínez, Eva Muñoz‐Couselo et al. · Clinical & Translational Oncology · 2020 · 33 citations · Full text

Pharmacy, Oncology, Pharmacology +17